Nat Genet:SREBP依赖的脂肪生成途径的异常可以促进转移性前列腺癌

2018-01-24 AlexYang MedSci原创

脂肪要么是内源合成,要么是体外摄取,并且脂肪与人类前列腺癌有关。最近,有研究人员发现在转移性人类前列腺癌中(CaP),PML经常与PTEN存在共缺失情况。研究人员在文章中阐释了Pml在小鼠前列腺中的有条件的失活能够将无痛Pten-null肿瘤改变为致死性转移疾病。研究人员还鉴定了MAPK再激活、异常的SREBP前转移脂肪生成途径和不同的脂质沉积情况均为转移性Pml-null和Pten-null C

脂肪要么是内源合成,要么是体外摄取,并且脂肪与人类前列腺癌有关。最近,有研究人员发现在转移性人类前列腺癌中(CaP),PML经常与PTEN存在共缺失情况。

研究人员在文章中阐释了Pml在小鼠前列腺中的有条件的失活能够将无痛Pten-null肿瘤改变为致死性转移疾病。研究人员还鉴定了MAPK再激活、异常的SREBP前转移脂肪生成途径和不同的脂质沉积情况均为转移性Pml-nullPten-null CaP的关键特征特性。更多的是,在体内试验中,利用fatostatin以SREBP为靶标,可以阻断肿瘤生长和远距离转移。重要的是,高脂肪饮食(HFD)能够诱导脂肪在前列腺肿瘤中的积累,并且在CaP非转移性Pten-null小鼠模型中能够促使转移,并且在转移性人类CaP中,SREBP特性高度聚集。

最后,研究人员指出,他们的发现揭示了一个前转移脂肪生成途径,并且为西方HFD能够促进转移提供了遗传和实验证据。

原始出处:

Ming Chen, Jiangwen Zhang, Katia Sampieri et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nat Genet. 15 Jan 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882801, encodeId=45771882801d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 27 19:56:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048966, encodeId=7ad7204896634, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Sep 17 15:56:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686175, encodeId=8cc616861e5dd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Jul 11 08:56:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733970, encodeId=0d461e33970e1, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 08 20:56:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386356, encodeId=42dc138635647, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395531, encodeId=b402139553119, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-04-27 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882801, encodeId=45771882801d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 27 19:56:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048966, encodeId=7ad7204896634, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Sep 17 15:56:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686175, encodeId=8cc616861e5dd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Jul 11 08:56:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733970, encodeId=0d461e33970e1, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 08 20:56:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386356, encodeId=42dc138635647, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395531, encodeId=b402139553119, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-09-17 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882801, encodeId=45771882801d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 27 19:56:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048966, encodeId=7ad7204896634, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Sep 17 15:56:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686175, encodeId=8cc616861e5dd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Jul 11 08:56:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733970, encodeId=0d461e33970e1, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 08 20:56:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386356, encodeId=42dc138635647, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395531, encodeId=b402139553119, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882801, encodeId=45771882801d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 27 19:56:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048966, encodeId=7ad7204896634, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Sep 17 15:56:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686175, encodeId=8cc616861e5dd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Jul 11 08:56:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733970, encodeId=0d461e33970e1, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 08 20:56:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386356, encodeId=42dc138635647, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395531, encodeId=b402139553119, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-08-08 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882801, encodeId=45771882801d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 27 19:56:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048966, encodeId=7ad7204896634, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Sep 17 15:56:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686175, encodeId=8cc616861e5dd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Jul 11 08:56:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733970, encodeId=0d461e33970e1, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 08 20:56:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386356, encodeId=42dc138635647, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395531, encodeId=b402139553119, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1882801, encodeId=45771882801d2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 27 19:56:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048966, encodeId=7ad7204896634, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Mon Sep 17 15:56:00 CST 2018, time=2018-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686175, encodeId=8cc616861e5dd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Wed Jul 11 08:56:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733970, encodeId=0d461e33970e1, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Aug 08 20:56:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386356, encodeId=42dc138635647, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395531, encodeId=b402139553119, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Fri Jan 26 11:56:00 CST 2018, time=2018-01-26, status=1, ipAttribution=)]

相关资讯

Oncogenesis:在增生早期上皮细胞中,前列腺特异性PTen缺失能够激活炎症micro表达通路

PTen的缺失在前列腺癌的起始阶段和晚期代谢阶段是一种最为常见的事件。前列腺特异性probasin介导的Pten缺失小鼠模型能够导致前列腺上皮内瘤样病变(PIN),从而导致恶性腺瘤。最近,有研究人员利用该模型,分析了Pten -/- PIN 与年龄匹配的野生型前列腺组织的miR和mRNA转录组情况,并且分析了Pten缺失在早期肿瘤发展过程中对miR的影响。研究发现,Pten缺失能够显著的改变超过2

Cancer Biomark:lncRNA ANRIL的过表达能够促进前列腺癌细胞的增殖和迁移

长非编码RNAs(lncRNAs)在肿瘤发生中具有关键的作用。然而,在前列腺癌中,lncRNAs(尤其是ANRIL)的角色和机制仍旧不清楚。最近,有研究人员利用CCK-8实验和转板迁移测定法调查了ANRIL对前列腺癌细胞增殖和迁移的影响,还利用定量PCR和蛋白免疫印迹实验分析了ANRIL、let-7a、TGF-β1、p-Smad2和p-Smad7的表达水平。研究结果表明,ANRIL在前列腺癌组织中

Brit J Cancer:机器人辅助根治性前列腺切除术和腹腔镜与开腹耻骨后前列腺癌根治术治疗结果比较研究

机器人辅助根治性前列腺切除术(RAPR)已经被人们快速的采用,并且还是在腹腔镜前列腺癌根治术(LRP)或者腹腔镜与开腹耻骨后前列腺癌根治术(ORP)与RARP治疗结果比较缺乏大量证据的情况下发生的。最近,有研究人员比较了病人报道的RARP、LRP或者ORP治疗结果。参与者来自英格兰且患有前列腺癌的男性,并且他们都经历过根治性前列腺癌切除术,研究人员在诊断后18个月进行了调查问卷,还利用了线性回归评

Proteomes:尿液比较蛋白组学分析阐释了急性期反应信号和LXR/RXR激活通路在前列腺癌中下调

利用非侵入型诊断标记来检测前列腺癌(PCa)仍旧是一种挑战。最近,有研究人员对尿蛋白进行了鉴定,旨在鉴定出能够在早期阶段对PCa具有足够敏感性和特异性检测的尿蛋白。研究人员对患有PCa、良性前列腺增生、膀胱癌和肾癌的病人,结合生物信息学分析,进行了尿液的比较蛋白组学分析。研究发现,在2-D DIGE/MS和无标签LC-MS/MS实验中,分别有20个和85个蛋白在丰度上具有统计学显著差异。信息学分析

Prostate Cancer P D:原发性肿瘤中p53状态可以预测阿比特龙和恩杂鲁胺在去势难治性前列腺癌中的疗效

最近,有研究人员测试了是否在原发性肿瘤中,基于组织的p53和PTEN基因组状态能够预测阿比特龙和恩杂鲁胺在去势难治性前列腺癌(CRPC)中的敏感性。研究人员进行了一项回顾性的分析,包括了309名患有CRPC且接受阿比特龙或恩杂鲁胺治疗的连续性病人。在这些病人中,101名男性(33%)具有可以用于分析的原发性肿瘤组织。研究人员利用基因验证免疫组织化学分析筛选了有害的TP53错义突变和PTEN缺失,并

Mol Med Rep:YAP敲除能够抑制人类前列腺癌DU145细胞的增殖和诱导其凋亡

最近,有研究人员探究了YAP蛋白在人类前列腺癌DU145细胞中的角色和它的潜在的分子机制。研究人员起始时检测了YAP在DU145细胞中的表达水平,并且阐释了YAP在这些细胞中具有高水平的表达。为了调查YAP在DU145细胞中的角色,研究人员利用YAP小干扰RNA产生了一个稳定的YAP沉默的DU145细胞系,还利用RT-PCR技术和蛋白免疫技术分别检测了mRNA和蛋白。另外,研究人员还利用了MTT实